1022150-11-3

基本信息
依鲁替尼杂质47
依鲁替尼杂质BOC
依鲁替尼杂质1对照品
[3,4-D]嘧啶-1-基]哌啶-1-羧酸叔丁酯
(R)-3-[4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶-1-基]哌啶-1-羧
(R)-1-(1-BOC-3-哌啶基)-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶-4-胺
(R)-3-[4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶-1-基]哌啶-1-羧酸叔丁酯
(R)-3-[4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶-1-基]哌啶-1-羧酸叔丁酯 IBL6
N-BOC-IBRUTINIB ( TERT-BUTYL-1-CARBOXYL PIPERIDINE ANALOG OF IBRUTINIB)
Ibrutinib iMpurity Boc
Ibrutinib Intermediates
(R)-tert-butyl 3-(4-amino-3-(4-phenoxyphenyl)-
3-[4-Amino-3-(4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-y...
N-Boc-Ibrutinib ( tert-Butyl-1-carboxyl Piperidine analog of Ibrutinib)
(R)-1-(1-Boc-3-piperidinyl)-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
(R)-tert-Butyl 3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-ca
(R)-3-[4-Amino-3-(4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-piperidine-1-carboxylic acid
tert-butyl (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate
物理化学性质
制备方法
![(3R)-1-BOC-3-(4-氨基-3-碘-1H-吡唑并[3,4-D]嘧啶-1-基)哌啶](/CAS/20150408/GIF/1276110-38-3.gif)
1276110-38-3

51067-38-0
![(R)-3-[4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-D]嘧啶-1-基]哌啶-1-羧酸叔丁酯](/CAS/20150408/GIF/1022150-11-3.gif)
1022150-11-3
步骤4A: 在氮气保护下,将(R)-3-(4-氨基-3-碘-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯(1g,2.25mmol,1.00当量)、4-苯氧基苯基硼酸(530mg,2.48mmol,1.10当量)、碳酸钠(480mg,4.53mmol,2.01当量)和四(三苯基膦)钯(78mg,0.07mmol,0.03当量)溶于二恶烷(60mL)和水(15mL)的混合溶剂中。将反应混合物在90℃下搅拌24小时。反应完成后,将混合物冷却至室温,随后在减压下浓缩。将残余物溶解于二氯甲烷(500mL)中,所得溶液用水(200mL)洗涤,无水硫酸钠干燥,再次减压浓缩。粗产物通过硅胶柱色谱法纯化,洗脱剂为二氯甲烷/甲醇(100/1,v/v),得到700mg(产率64%)的(R)-3-(4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-甲酸叔丁酯,为黄色固体。
参考文献:
[1] Patent: WO2012/158795, 2012, A1. Location in patent: Page/Page column 76
[2] Patent: WO2013/191965, 2013, A1. Location in patent: Page/Page column 156
[3] Patent: WO2014/22569, 2014, A1. Location in patent: Page/Page column 50
[4] Patent: US8673925, 2014, B1. Location in patent: Page/Page column 201
[5] Patent: CN106146511, 2016, A. Location in patent: Paragraph 0150; 0151; 0152